TARA is a €6 million Horizon Europe health innovation project in which ESRA is involved, together with 10 organizations from 7 countries. Project is delivering a new generation of non-surgical migraine therapy designed to be effective, affordable, and deployable in everyday clinical practice—including resource-limited healthcare settings. By combining minimally invasive neurostimulation with digital health technologies, TARA addresses a major unmet need in migraine care: scalable access to advanced treatment without the burden of complex surgery or specialist infrastructure.
Minimally Invasive, Maximum Impact
At the heart of TARA is a percutaneous implantable neurostimulation device that can be inserted under local anaesthesia in an outpatient setting. This approach dramatically reduces procedural risk, recovery time, and cost compared to traditional implantable therapies—while delivering strong therapeutic potential. Designed for both patients and clinicians, the system enables wider adoption across diverse healthcare environments.
A Fully Integrated Digital Health Ecosystem
Supporting the implant, TARA offers a comprehensive digital ecosystem:
Together, these elements streamline the care pathway, making migraine treatment patient-centred, practical, and scalable.
Technological Breakthroughs
SENSIPLUS Chip: A tiny 1.5 × 1.5 mm multi-sensor microelectronic platform that processes physiological data on-chip using AI-based algorithms. It enables real-time, in-vivo monitoring and closed-loop neurostimulation, supporting the emerging Healthcare 5.0 paradigm.
OPORA Health App: Empowers patients and clinicians with intuitive control, personalised therapy, and remote monitoring. Its quality and innovation were recognised with the Seal of Excellence by Seeds of Bravery, funded by the European Innovation Council.
TARA is designed for real-world application. The LUNA platform, developed by Capri Medical, introduces a minimally invasive, injectable delivery system to improve migraine prediction and treatment. Clinical feasibility has been validated through three cadaver workshops held in Geneva, organized by ESRA and led by Professor Sam Eldabe (Consultant Anaesthetist, ESRA), where the delivery system’s characteristics for patient procedures were defined, helping refine techniques and enhance clinician confidence.
As an active member of the TARA consortium, ESRA, alongside the University of Pisa leading the project, has actively promoted TARA. The project’s visibility has been strengthened through dedicated sessions on migraine issues at ESRA congresses, as well as distribution of promotional materials, highlighting the innovative impact of TARA across the clinical community.
With TARA, the future of migraine therapy is safer, smarter, and more accessible than ever—bringing hope to millions of patients across Europe and beyond.
Discover more about the project and its innovations at the official TARA website: https://www.tara-project.eu/partners
We treat your personal data with care, view our privacy notice.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
